We have now completed our journey across Denmark, Sweden, Finland and Norway.
Four countries.
Four distinct strengths.
One shared evidence philosophy.
Denmark – deeply integrated national registries and a strong epidemiological tradition
Sweden– clinically rich quality registries embedded in routine care
Finland – structured secondary-use frameworks and clear data governance pathways
Norway– longitudinal linkage across the full patient journey
What defines the Nordics is not scale alone.
It is:
➡️ Universal healthcare coverage
➡️ Personal identifiers enabling cross-sector linkage
➡️ Decades of registry investment
➡️ High societal trust
➡️ Governance designed for responsible secondary use
For life science stakeholders, this translates into:
▶️ Comparator-ready populations
▶️ Real-world safety and utilisation insights
▶️ Evidence aligned with HTA expectations
▶️ Decision-grade RWE across the product lifecycle
The Nordic region remains one of the most mature environments globally for regulatory- and access-relevant real-world evidence.
And importantly, the infrastructure continues to evolve.
How do you see the Nordics shaping the next phase of RWE-driven development and access?
